AstraZeneca Crestor Defense Minimizes Risk Of High Dose, FDA Says

An AstraZeneca newspaper ad defending the safety of Crestor improperly suggests that all doses of rosuvastatin are "just as safe" as other statins, FDA says in a Dec. 21 "untitled" letter to the company

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet